CHANGZHOU FDA Thursday, November 5, 2026 +0.70 Positive

FDA Approves Unknown Drug — CHANGZHOU PHARM

CHANGZHOU PHARM received FDA approval for its application ANDA221019 on November 5, 2026, signaling a significant entry into the pharmaceutical market that will likely provide safer, more accessible alternatives for patients and intensify competitive pressure on existing brand-name products.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed